Plasma treatment for growth factor release from cells and tissues
US8906659B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2010 |
| Grant date | Dec 9, 2014 |
| Priority date | — |
| Expiry date | Mar 16, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2500/02
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Aspects of the present invention are related to methods comprising contacting an endothelial cell in an endothelial cell population with a non-thermal plasma to release an angiogenic growth factor. The released angiogenic growth factor may induce endothelial cell proliferation. In certain embodiments, the angiogenic growth factor is fibroblast growth factor-2. Preferably, the non-thermal plasma may be an atmospheric pressure dielectric barrier discharge. Additional aspects of the present invention are directed to methods for treating a disease comprising promoting angiogenesis by contacting an endothelial cell in a endothelial cell population with a non-thermal plasma to release an angiogenic growth factor. The angiogenic growth factor may induce endothelial cell proliferation. Further aspects of the present invention are directed to methods for treating a disease comprising inhibiting angiogenesis by contacting an endothelial cell in a endothelial cell population with a non-thermal plasma to reduce the number of endothelial cells in the population.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.